Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.32 +10.0%	$1.74	$0.40 ▼ $3.10	$187.04M	2.09	2.18 million shs	8.05 million shs
DARE Dare Bioscience	$2.82 -3.4%	$2.96	$2.67 ▼ $5.76	$24.96M	1.2	36,850 shs	71,435 shs
FIXX Homology Medicines		$1.18	$0.46 ▼ $17.51	$978.01M	-0.1	390,307 shs	22,300 shs
HOWL Werewolf Therapeutics	$1.19 -4.0%	$1.07	$0.60 ▼ $4.18	$53.40M	0.65	443,093 shs	282,065 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	-15.64%	+4.04%	+246.27%	+79.84%
DARE Dare Bioscience	0.00%	-6.93%	-2.76%	-2.08%	-45.91%
FIXX Homology Medicines	0.00%	0.00%	0.00%	0.00%	0.00%
HOWL Werewolf Therapeutics	0.00%	-2.46%	+3.48%	+6.25%	-58.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTMX CytomX Therapeutics	4.1329 of 5 stars	3.5	1.0	4.7	2.5	1.7	1.3
DARE Dare Bioscience	1.1815 of 5 stars	3.3	3.0	0.0	0.6	0.0	0.0
FIXX Homology Medicines	0.6998 of 5 stars	0.0	0.0	4.8	0.6	0.8	0.6
HOWL Werewolf Therapeutics	3.0675 of 5 stars	3.5	3.0	0.0	0.6	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$5.33	129.89% Upside
DARE Dare Bioscience	2.50	Moderate Buy	$12.00	325.53% Upside
FIXX Homology Medicines	0.00	N/A	N/A	N/A
HOWL Werewolf Therapeutics	3.00	Buy	$8.33	600.28% Upside

Current Analyst Ratings Breakdown

Latest FIXX, HOWL, CTMX, and DARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/9/2025	HOWL Werewolf Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $6.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
4/1/2025	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$138.10M	1.35	$0.36 per share	6.41	($0.01) per share	-232.00
DARE Dare Bioscience	$10K	2,495.70	N/A	N/A	($0.69) per share	-4.09
FIXX Homology Medicines	$1.16M	0.00	N/A	N/A	$1.26 per share	0.00
HOWL Werewolf Therapeutics	$1.88M	28.40	N/A	N/A	$1.65 per share	0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	$31.87M	$0.48	4.83	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
DARE Dare Bioscience	-$4.05M	-$0.17	N/A	N/A	N/A	-191.65%	N/A	-8.14%	8/11/2025 (Estimated)
FIXX Homology Medicines	-$112.96M	-$1.96	N/A	N/A	N/A	-4,779.31%	-102.52%	-74.91%	N/A
HOWL Werewolf Therapeutics	-$70.51M	-$1.67	N/A	N/A	N/A	N/A	-89.37%	-54.87%	8/14/2025 (Estimated)

Latest FIXX, HOWL, CTMX, and DARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	DARE Dare Bioscience	-$0.63	-$0.50	+$0.13	-$0.50	$0.60 million	$0.03 million
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/8/2025	Q1 2025	HOWL Werewolf Therapeutics	-$0.44	-$0.40	+$0.04	-$0.40	$0.30 million	N/A
3/31/2025	Q4 2024	DARE Dare Bioscience	-$0.66	-$0.64	+$0.02	-$0.64	$1.00 million	($0.06) million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
FIXX Homology Medicines	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	1.73	1.73
DARE Dare Bioscience	N/A	0.56	0.56
FIXX Homology Medicines	N/A	7.25	7.25
HOWL Werewolf Therapeutics	0.46	8.09	8.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
DARE Dare Bioscience	6.70%
FIXX Homology Medicines	31.32%
HOWL Werewolf Therapeutics	64.84%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	6.60%
DARE Dare Bioscience	4.00%
FIXX Homology Medicines	16.10%
HOWL Werewolf Therapeutics	23.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
DARE Dare Bioscience	30	8.85 million	8.50 million	Not Optionable
FIXX Homology Medicines	7	58.13 million	48.77 million	Optionable
HOWL Werewolf Therapeutics	40	44.87 million	34.28 million	Optionable

FIXX, HOWL, CTMX, and DARE Headlines

Recent News About These Companies

Werewolf Therapeutics to Participate in the BIO International Convention

June 12, 2025 | globenewswire.com

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Sold by Millennium Management LLC

June 6, 2025 | marketbeat.com

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

May 29, 2025 | zacks.com

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Werewolf Therapeutics’ SWOT analysis: innovative platform drives stock potential

May 24, 2025 | investing.com

Werewolf Therapeutics Stock Price, Quotes and Forecasts

May 20, 2025 | benzinga.com

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

May 20, 2025 | globenewswire.com

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Acquires $159,288.22 in Stock

May 15, 2025 | insidertrades.com

Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit

May 13, 2025 | globenewswire.com

Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025 | finanznachrichten.de

Werewolf Therapeutics Announces Q1 2025 Financial Results

May 9, 2025 | msn.com

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

Werewolf Therapeutics reports progress on IBD treatment

May 6, 2025 | investing.com

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

May 5, 2025 | globenewswire.com

Listening to the Desert’s “Werewolf Mouse” Reveals the Complex World of Bioacoustics

May 1, 2025 | marfapublicradio.org

Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline

April 25, 2025 | zacks.com

Werewolf Therapeutics appoints Bloom as Chief Business Officer

April 17, 2025 | markets.businessinsider.com

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

April 17, 2025 | quiverquant.com

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

April 17, 2025 | globenewswire.com

Watch: First dire wolf’s howl for 10,000 years after scientists bring extinct species ‘back to life’

April 8, 2025 | msn.com

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FIXX, HOWL, CTMX, and DARE Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.32 +0.21 (+9.95%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.35 +0.03 (+1.08%)

As of 06/20/2025 07:38 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Dare Bioscience NASDAQ:DARE

$2.82 -0.10 (-3.42%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.82 +0.01 (+0.18%)

As of 06/20/2025 04:43 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Homology Medicines NASDAQ:FIXX

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Werewolf Therapeutics NASDAQ:HOWL

$1.19 -0.05 (-4.03%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.23 +0.04 (+2.94%)

As of 06/20/2025 06:53 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time